Clinical Trial

Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention

Study acronym: PRESTIGE-AMI
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated June 26, 2025 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
We aimed to identify whether SGLT-2 inhibitor administration before and after coronary intervention is effective in reducing the size of infarction and myocardial remodeling in patients with acute myocardial infarction (AMI) and high risk of heart failure, and its mechanism. For this reason, we compared cardiac magnetic resonance imaging (CMR) parameters and clinical outcomes between the SGLT-2 inhibitor group and the control group to confirm the efficacy and safety of SGLT-2 inhibitors.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-05-19; most recent amendment 2025-06-22.
Status change: Not Yet Recruiting → Recruiting 2021-08-11
Trial Details
NCT Number NCT04899479
Lead Sponsor Samsung Medical Center
Conditions Acute Myocardial Infarction, Heart Failure
Enrollment 200 participants
Start Date 2021-07-05
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-26